Merrimack and Baxalta snag FDA fast-track promise; Teva moves forward with long-delayed MS drug;

@FierceBiotech: ICYMI yesterday: Little NeuroRx boasts big about a new ketamine combo for bipolar depression. Article | Follow @FierceBiotech

@JohnCFierce: Isn't it strange that biotech is booming and R&D jobs have never been so uncertain? | Follow @JohnCFierce

> Teva ($TEVA) and partner Active Biotech have wrapped up enrollment in a Phase III trial on the long-delayed multiple sclerosis drug laquinimod, expecting to post final results in 2017 and finally complete an FDA submission thereafter. More

> Merrimack Pharmaceuticals ($MACK) and Baxter's ($BAX) Baxalta picked up the FDA's priority-review designation for their MM-398, an in-development treatment for pancreatic cancer. The agency has promised to hand down a final decision on the drug by Oct. 24. News

> Egalet's ($EGLT) abuse-deterrent oral morphine candidate demonstrated bioequivalence to MS Contin, Purdue Pharma's top-selling morphine. Item

Medical Device News

@FierceMedDev: Google and the Broad Institute join forces for genomic data sharing. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Chris Viehbacher explains: "If I had $2 billion to invest…" More from FierceBiotech | Follow @VarunSaxena2

@EmilyWFierce: Enthusiasm could be outpacing the evidence when it comes to genetic testing, experts say. More from the NYT | Follow @EmilyWFierce

> Zimmer Biomet is born after knee implant divestiture to S&N. More

> FDA panel slated to weigh Bayer Essure safety after more than 5,000 complaints. Story

> Covidien settles the score in more than 11,000 vaginal mesh cases. Report

Pharma News

@FiercePharma: HIV vaccine research a 'major advance,' NIH official says. FierceVaccines story | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. Feature from FiercePharmaManufacturing | Follow @EricPFierce

> Eli Lilly faces August trials in suits over Cymbalta withdrawal symptoms. Story

> CDC panel disappoints Pfizer, GSK with limited backing for meningitis B shots. Article

> Allergan CEO: 'The cuts are done' at layoffs-plagued Irvine campus. More

Vaccines News

> Vical posts herpes vaccine PhI/II failure, gutting shares. News

> MERS getting more attention as vaccine candidate enters PhI. More

> ACIP gives Glaxo, Pfizer a lukewarm decision for new meningitis B vaccines. Story

> NIH grants Northeastern prof $1.4M to address 'bottleneck' in vaccine development. Article

> Pfizer to acquire GlaxoSmithKline meningitis vaccines for $130M. Report

CRO News

> PRA debuts a sweeping clinical trial operating system. More

> Novasep bets $11M on armed antibody R&D. Item

> Huntingdon and Harlan move forward under a new monicker. Article

> Icon rolls out some new patient-consent tech with a focus on education. Story

> Parexel cutting 850 jobs as it dims its revenue outlook. Report

Pharma Asia News

> S. Korea sees extra $9B in spending to handle MERS outbreak. Report

> Australia's Benitec heading for Nasdaq IPO. More

> Ascletis plans China, Taiwan PhIII trials on chronic hep C therapies. Story

> CRO M&A ticks up in India, fueling hopes of turnaround. Article

> South Korea biopharma IPOs highlight demand. Item

Pharma Manufacturing News

> Novasep building ADC manufacturing plant at Le Mans site. News

> Pharmacies want more time to comply with track-and-trace rules. Item

> TxCell halts drug production, a decision made with French regulator. Report

> FDA slaps U.S. drugmaker over drug testing issues. Story

> Hospira finally up and running at its cost-cutting India plant. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.